Symic developing synthetic proteoglycan mimics for vascular access, OA
Symic Biomedical Inc. is developing a library of synthetic mimics that function like natural proteoglycans but are easier to manufacture and aren't susceptible to enzymatic degradation, opening up previously untapped therapeutic space.
Proteoglycans, which are found in the extracellular matrix, are a class of complex macromolecules composed of a core protein onto which glycosaminoglycan side chains are attached. The exact role of the proteoglycan depends on its components and tissue location.
CEO Ken Horne said low expression